1. Pulmonary recovery from COVID-19 in patients with metabolic diseases: a longitudinal prospective cohort study.
- Author
-
Sonnweber, Thomas, Grubwieser, Philipp, Pizzini, Alex, Boehm, Anna, Sahanic, Sabina, Luger, Anna, Schwabl, Christoph, Widmann, Gerlig, Egger, Alexander, Hoermann, Gregor, Wöll, Ewald, Puchner, Bernhard, Kaser, Susanne, Theurl, Igor, Nairz, Manfred, Tymoszuk, Piotr, Weiss, Günter, Joannidis, Michael, Löffler-Ragg, Judith, and Tancevski, Ivan
- Subjects
COVID-19 ,METABOLIC disorders ,NEUROENDOCRINE cells ,COHORT analysis ,LONGITUDINAL method - Abstract
The severity of coronavirus disease 2019 (COVID-19) is related to the presence of comorbidities including metabolic diseases. We herein present data from the longitudinal prospective CovILD trial, and investigate the recovery from COVID-19 in individuals with dysglycemia and dyslipidemia. A total of 145 COVID-19 patients were prospectively followed and a comprehensive clinical, laboratory and imaging assessment was performed at 60, 100, 180, and 360 days after the onset of COVID-19. The severity of acute COVID-19 and outcome at early post-acute follow-up were significantly related to the presence of dysglycemia and dyslipidemia. Still, at long-term follow-up, metabolic disorders were not associated with an adverse pulmonary outcome, as reflected by a good recovery of structural lung abnormalities in both, patients with and without metabolic diseases. To conclude, dyslipidemia and dysglycemia are associated with a more severe course of acute COVID-19 as well as delayed early recovery but do not impair long-term pulmonary recovery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF